Perrigo Company stock analysis
Perrigo Company (0Y5E) Share Price & Analysis
0Y5E Stock Chart & Stats
- Day’s Range
- $15.82 - $16.44
- 52-Week Range
- $9.28 - $17.25
- Previous Close
- $16.31
- Volume
- N/A
- Average Volume (3M)
- 1,871
- Market Cap
- $2.25B
- Enterprise Value
- $5.17B
- Total Cash (Recent Filing)
- $436.60M
- Total Debt (Recent Filing)
- $3.45B
- Price to Earnings (P/E)
- ―
- Beta
- 1.86
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- 0.82
- Next Dividend Ex-Date
- Nov 27, 2026
- Dividend Yield
- 7.11%
Bulls Say, Bears Say
Bulls Say
Positive Cash Generation
Perrigo continues to generate positive operating and free cash flow despite reported net losses, providing liquidity to support operations and investment. Although cash generation has weakened, this recurring cash base can help fund the core business and reduce financial strain while profitability is repaired.
Market Share Gains
Share gains in U.S. store-brand OTC and key European brands indicate that Perrigo is strengthening its position in important self-care channels. Sustained gains can improve retailer relationships, support volume resilience, and reinforce the scale advantages of its private-label and branded portfolio.
Portfolio Simplification
Divesting infant formula should concentrate management attention and capital on Perrigo's core consumer self-care activities. The stated reduction in future capital requirements and potential margin improvement could strengthen resource allocation, simplify execution, and support more durable operating performance.
Bears Say
Deep Profitability Weakness
Perrigo's severe net losses and deeply negative margin indicate that current earnings power is not supporting the business adequately. The deterioration is more serious than modest revenue softness, and continued losses could restrict reinvestment, weaken shareholder returns, and prolong the recovery in profitability.
Declining Sales Outlook
The lowered sales outlook points to persistent demand and channel pressure rather than a single quarter's fluctuation. European weakness, cautious retailer inventory positioning, and lower category volumes may limit near-term revenue recovery and make it harder for operating leverage to rebuild margins.
High Financial Leverage
High leverage reduces Perrigo's financial flexibility while earnings and sales remain under pressure. A substantial debt burden can absorb cash through interest and repayment needs, constrain investment in the core portfolio, and make the company more sensitive to further operating underperformance.
0Y5E FAQ
What was Perrigo Company’s price range in the past 12 months?
What is Perrigo Company’s market cap?
When is Perrigo Company’s upcoming earnings report date?
How were Perrigo Company’s earnings last quarter?
Is Perrigo Company overvalued?
Does Perrigo Company pay dividends?
What is Perrigo Company’s EPS estimate?
How many shares outstanding does Perrigo Company have?
What happened to Perrigo Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Perrigo Company?
What is the TipRanks Smart Score and how is it calculated?
Perrigo Company Stock Smart Score
Company Description
Perrigo Company
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Albert A. Manzone
- Employees
- 8,100
- Website
- www.perrigo.com
- Address
- The Sharp Building, Dublin, DU, D02 TY74, IE
Perrigo Company (0Y5E) Earnings & Revenues
0Y5E Company Deck
0Y5E Earnings Call
Earnings Call SentimentNeutral
The call presented a mixed but improving picture. Perrigo reported sequential improvement in core sales trends and operating margins, meaningful share gains in U.S. store brand OTC and European brands, progress on its Three-S plan, cost savings and a strategically important infant formula divestiture. However, Q3 sales, margins and EPS declined, the company lowered its outlook because of cautious retailer inventory positioning and continued European softness, and leverage remains elevated. The positive strategic and operational developments were offset by significant current-period financial pressures.
View all GB:0Y5E earnings summaries0Y5E Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 5 | 1 |
| Technical Analysis | 5 | 5 | 0 |
| Moving Averages | 11 | 0 | 1 |












